Lumida
/TWST
⌘K
Twist Bioscience Corp

Twist Bioscience Corp

TWST
$127.22USD+0.29%+0.37 today

MARKET CAP

8.4B

P/E (TTM)

FWD P/E

DAY RANGE

$126 – $130

52W RANGE

$23
$155

AI Summary

Stalk
StalkMedium

TWST remains in a Stage 2 uptrend above rising SMAs, but is undergoing a descending retracement into declining short-term EMAs. The medium-term bias is bullish, supported by the mean-reversion pattern suggesting support near the 50-day SMA. However, short-term price action shows a pullback without clear bounce signals, so execution is deferred until a clearer recovery emerges.

  • Q3 revenue $118.4M (+23% YoY) with 14th consecutive growth quarter; FY26 guide raised to $456M.
  • NGS segment revenue $61.8M (+12% YoY) from 657 clients, signaling market share gains.
  • Earnings yield is negative, indicating weak return generation and potential overvaluation.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$132.3M$203.6M$245.1M$313.0M$376.6M
YoY %+46.9%+53.8%+20.4%+27.7%+20.3%
P / Sales39.0x9.3x4.4x8.4x4.5x
EV / Sales36.4x8.3x3.9x8.1x4.4x
Gross Profit, Adj.$51.7M$84.2M$89.7M$133.3M$191.0M
YoY %+80.2%+62.9%+6.5%+48.6%+43.2%
Margin %39.1%41.4%36.6%42.6%50.7%
EV / Gross Profit93.1x20.1x10.7x19.0x8.7x
EBITDA, Adj.$-143.5M$-218.3M$-177.6M$-144.5M$-111.4M
YoY %-29.4%-52.1%+18.6%+18.7%+22.9%
Margin %-108.4%-107.2%-72.5%-46.2%-29.6%
EV / EBITDA-33.6x-7.8x-5.4x-17.6x-15.0x
EBIT$-152.7M$-230.2M$-217.2M$-220.8M$-136.3M
YoY %-9.0%-50.7%+5.7%-1.7%+38.3%
Margin %-115.4%-113.1%-88.6%-70.6%-36.2%
EV / EBIT-31.5x-7.4x-4.4x-11.5x-12.2x
Net Income$-152.1M$-217.9M$-204.6M$-208.7M$-77.7M
YoY %-8.7%-43.2%+6.1%-2.0%+62.8%
Net Margin-114.9%-107.0%-83.5%-66.7%-20.6%
EPS (GAAP)-$3.15-$4.04-$3.60-$3.60-$1.30
YoY %+11.8%-28.3%+10.9%+63.9%